ROLE OF RIFAXIMIN ON FRAILTY (MUSCLE WEAKNESS) IN DECOMPENSATED CIRRHOSIS (CHRONIC LIVER DISEASE)

Not Applicable

Completed

• Conditions: Health Condition 1: K746- Other and unspecified cirrhosis ofliver

• Registration Number: CTRI/2023/01/048824
• Lead Sponsor: PGIMER

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2023-05-15
• Last Update Posted: 19 December 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

1. Age 18-75 years

2. Patient of decompensated cirrhosis of any aetiology

3. Presence of frailty

Exclusion Criteria

1. Patients with CTP score more than 10

2. Patients with history of hepatic encephalopathy

3. Patient with acute on chronic liver failure (ACLF)

4. Obese patient (BMI;25kg/m2)

5. Patients with active malignancy, hepatocellular carcinoma and end- stage renal disease

6. Patients having prior study enrolment or enrolment in another conflicting study.

7. Patients, who are not willing to participate in the study.

8. Patients who are participating in other clinical trials within past 3 months.

9. Patients who has an active evidence of infection

10. Patients who had acute organic brain disease in the past 6 months

11. Patients who has severe hemodynamic instability, serious heart disease, severe bradycardia or tachycardia at rest

12. Patients having renal failure (creatinine clearance rate =60 mL/min/1.73 m2).

13. Patients with severe cognitive impairment (Mini-Mental State Examination =17), overt hepatic encephalopathy or patients who had physical disability.

14. Patients with HIV

15. Pregnancy

16. Post liver transplant patients

17. Exposure to rifaximin in the previous 12 weeks

18. Patients receiving concomitant secondary prophylaxis for SBP

19. Known hypersensitivity to Rifaximin

Study & Design

• Study Type: Interventional
• Study Design: Not specified